Information on the conclusion of contracts for the acquisition of series H ordinary shares
Current report no. 52/2021
Legal basis: Legal basis: Art. 17 sec. 1 of MAR – confidential information
With reference to the current report No. 24/2021 and previous reports on the increase of the share capital through the issue of series H shares (“Series H Shares”), the Management Board of Medicalgorithmics S.A. with its registered office in Warsaw (“Company”, “Issuer”) hereby informs that the Company has received information today about the acceptance by investors of the offers submitted by the Company for a total of 648,556 (six hundred and forty-eight thousand five hundred and fifty-six) Series H Shares, therefore the Company hereby informs that it has concluded agreements with investors for the subscription of 648,556 (six hundred and forty-eight thousand five hundred and fifty-six) Series H Shares with the total value understood as the product of the number of Series H Shares subscribed for and the Series H Share issue price of PLN 18.00 (eighteen) per one Series H Share in the amount of PLN 11,674,008.00 (eleven million six hundred seventy four thousand eight zlotys 00/100).
Moreover, the Issuer’s Management Board informs that the required cash contributions to cover the Series H Shares have been made in full.
The advisors in the offer of the Company’s Series H Shares were: (i) Q Securities S.A. , who acted as the Offer Manager and Bookrunner, and (ii) CC Group sp.z o.o., who acted as the Company’s financial advisor.
This current report is for informational purposes only. This current report is not intended to be used in any way, directly or indirectly, promoting the subscription of the shares of the new issue of the Issuer and is not promotional material prepared or published by the Company for the purpose of promoting or subscribing for the shares of the new issue or encouraging, directly or indirectly, to take them up. The company has not yet published any materials aimed at promoting or subscribing for the new issue of shares. This document does not constitute an issue prospectus or other offering document, the preparation of which is not expected in connection with the issue of shares by the Company.
This material, or any part of it, is not intended for distribution, directly or indirectly, in or to the United States of America or in other countries where public dissemination of the information contained in this material may be restricted or prohibited by law. The securities in question in this material, have not been and will not be registered under the US Securities Act of 1933 and may not be offered or sold in the territory of the United States of America, except for transactions that are not subject to registration provided for in the US Act on Securities or pursuant to an exception to such registration obligation.
It is not subject to dissemination, publication or distribution, directly or indirectly, in or to the United States of America, Australia, Canada, Japan or any other jurisdiction, in which it is subject to restrictions or is not allowed.